Management Committee

H. Thomas Watkins

President and Chief Executive Officer

H. Thomas Watkins joined HGS as Chief Executive Officer and a Director in December 2004, and was also named President in December 2005. Mr. Watkins came to HGS with nearly twenty years of experience at Abbott Laboratories and its affiliates in the U.S. and Asia. Mr. Watkins began his career in 1974 with Arthur Andersen & Co., and was a management consultant with McKinsey and Company, Inc., from 1979 to 1985. He holds a bachelor’s degree from the College of William and Mary, and a master’s degree in business administration from the University of Chicago Graduate School of Business. Mr. Watkins is Chair of the Board of Directors of the Biotechnology Industry Organization (BIO) and Chair of the Life Sciences Advisory Board of the State of Maryland. He is a member of the Boards of Directors of Vanda Pharmaceuticals, Inc., the U.S. Chamber of Commerce, and the National Symphony Orchestra. He is also Chair of The College of William and Mary Foundation Board of Trustees and a member of the Board of Trustees of The Mason School of Business of The College of William and Mary.

James H. Davis, Ph.D., J.D.

Executive Vice President, General Counsel and Secretary

James H. Davis joined HGS as Senior Vice President, General Counsel and Secretary in May 1997. In December 2003, Dr. Davis was promoted to Executive Vice President. Prior to joining HGS, Dr. Davis was with the intellectual property law firm of Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P., where his practice focused on providing an integrated analysis of legal issues affecting the commercialization of new technologies, including intellectual property rights, regulatory compliance and licensing. Prior to joining Finnegan, Henderson in 1995, Dr. Davis served as General Counsel, Vice President of Research and Development, and a Director of Crop Genetics International Corporation, which he had joined in 1988 as General Counsel and Vice President of Development and Regulatory Affairs. Earlier in his career, Dr. Davis was a Partner with Weil, Gotshal & Manges, which he joined in 1986, with a practice principally concentrated on counseling and litigation relating to environmental, health, food, drug and cosmetic issues. From 1983 to 1985, he served with the U.S. Environmental Protection Agency. Dr. Davis holds a doctorate degree in Organic and Theoretical Chemistry from the California Institute of Technology, a law degree from the University of Virginia, and his Bachelor of Science and Master of Science in Chemistry degrees from Yale University. Dr. Davis serves on the Board of Directors of the Leukemia and Lymphoma Society.

Barry A. Labinger

Executive Vice President and Chief Commercial Officer

Barry A. Labinger joined HGS in August 2005 as Executive Vice President and Chief Commercial Officer. Mr. Labinger has more than 15 years of experience in the biopharmaceutical industry, including leadership of launches and marketing of a number of successful products in a variety of therapeutic areas. Mr. Labinger was most recently with 3M Pharmaceuticals, where he served as Division Vice President. 3M Pharmaceuticals is a global division of 3M Company with marketed products in dermatology, women’s health, and cardiac therapy, along with a pipeline of immune response modifiers for the treatment of viral infections and cancers. From 2000 to 2002, Mr. Labinger was Senior Vice President and General Manager, Commercial Operations, at Immunex Corporation where he led both the Enbrel and Specialty Therapeutics franchise teams and had direct responsibility for the sales and marketing organizations. Mr. Labinger also served as Senior Director of Diabetes Marketing and Director of Glucophage Marketing at Bristol-Myers Squibb. Mr. Labinger began his pharmaceutical career at Abbott Laboratories, where he was involved in the commercialization of products for gastrointestinal and infectious diseases. Mr. Labinger earned a Master of Business Administration degree from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Arts in economics from Northwestern University.  Mr. Labinger is a member of the Board of Directors of Anadys Pharmaceuticals, Inc.

David P. Southwell

Executive Vice President and Chief Financial Officer

David P. Southwell joined HGS as Executive Vice President and Chief Financial Officer in March 2010. Mr. Southwell served as a member of the HGS Board of Directors from July 2008 until resigning from the Board to accept his current position. Prior to joining the HGS Board, Mr. Southwell was Executive Vice President and Chief Financial Officer at Sepracor, Inc., a research-based pharmaceutical company. During his fourteen-year tenure as CFO at Sepracor, his responsibilities included raising over $2 billion in equity and convertible financings, spinning out three companies, and in-licensing complementary products. Prior to joining Sepracor, Mr. Southwell was Vice President, Investment Banking Division, at Lehman Brothers in New York, where he worked from 1984 to 1986, and from 1988 to 1994. Mr. Southwell graduated from Rice University, and received his M.B.A. from the Tuck School of Business at Dartmouth College. He is a member of the Board of Directors of PTC Therapeutics, Inc and THL Credit. He also serves as Chairman of the Tuck School of Business MBA Advisory Board.

David C. Stump, M.D.

Executive Vice President, Research and Development

David C. Stump joined HGS in November 1999 as Senior Vice President, Drug Development. In December 2003, he was promoted to Executive Vice President. In 2007, he was named Executive Vice President of Research & Development. Dr. Stump came to HGS from Genentech, Inc., where he was Vice President, Clinical Research, since 1995. In 1996, he was named a Genentech Fellow, only the second in Genentech’s history. Dr. Stump also served as a member of the Genentech Product Development Committee and chaired the Clinical Review Committee. While he was closely involved with overall clinical development efforts during his last five years at Genentech, Dr. Stump was most widely recognized for a decade of leadership of the company’s thrombolytic therapy drug development program, which accomplished multiple successful clinical trials and drug approvals for patients with acute myocardial infarction and acute ischemic stroke. Dr. Stump joined Genentech in 1989 from the University of Vermont where he was Associate Professor of Medicine and Biochemistry. He holds an A.B. from Earlham College and an M.D. from Indiana University. Dr. Stump received residency and fellowship training in internal medicine, hematology and oncology at the University of Iowa, where he also received advanced research training in biochemistry. In addition, he completed specialized training in hemostasis research as a visiting investigator at the University of Leuven, Belgium. Dr. Stump is certified by the American Board of Medicine, including its Medical Oncology and Hematology Subspecialty Boards. He holds membership in a variety of professional organizations and is an elected Fellow of the American College of Physicians and of the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. Dr. Stump is a member of the Boards of Trustees of Adventist HealthCare and Earlham College, and the Boards of Directors of Dendreon Corporation and Sunesis Pharmaceuticals, Inc.

Susan Bateson

Senior Vice President, Human Resources

Susan Bateson joined HGS as Vice President, Human Resources in January 1997. Ms. Bateson was promoted to Senior Vice President in December 2000. Prior to joining HGS, Ms. Bateson served as Director of Human Resources and Administration at the intellectual property law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. in Washington, D.C. Prior to joining Finnegan, Henderson in 1994, Ms. Bateson was employed by J.P. Morgan & Co. Incorporated, where she served in various leadership roles within Human Resources in the company's New York, Delaware, and London offices. Earlier in her career, Ms. Bateson held various human resources positions with Citicorp and was a financial analyst at Bankers Trust. Ms. Bateson earned her MBA in International Management from New York University's Stern School of Business and her B.A. cum laude in Economics from Mount Holyoke College. Ms. Bateson currently serves on the Board of Trustees of Mount Holyoke College, where she chairs the Trustee Conference Committee; as Chairperson of the Board of Advisors of The Universities at Shady Grove, in Rockville, Maryland; and on the Board of Directors of the Montgomery County Business Roundtable for Education.

Craig C. Parker

Senior Vice President, Strategy and Corporate Development

Craig C. Parker joined HGS in August 2011 as Senior Vice President, Strategy and Corporate Development. Prior to joining HGS, Mr. Parker was most recently CEO and co-founder of Vega Therapeutics, Inc., a biotechnology start-up focused on inflammation, obesity and insulin resistance. He was formerly Senior Vice President of Corporate Development and Finance and Chief Financial Officer of Proteolix Inc., a venture-backed development stage biotechnology company acquired by Onyx Pharmaceuticals in 2009. Prior to Proteolix, Mr. Parker was President of DCD BioConsulting LLC, a strategic and financial advisory firm to the biotechnology industry. From 2002-2007, Mr. Parker served as Managing Director and head of Biotechnology Equity Research at Lehman Brothers. His earlier career included senior executive positions in strategic planning and finance, biotechnology equity research and venture capital at Sprout Group, Immunex Corporation, Donaldson, Lufkin and Jenrette, and J.P. Morgan & Co. Mr. Parker received an AB degree in Biological Sciences from the University of Chicago and an MBA from the University of Michigan Ross School of Business, and did graduate work in Medicine and Cell Biology at the Georgetown University School of Medicine. He serves as a member of the Science Advisory Board of the Life Sciences Institute (LSI) at the University of Michigan and chairs the Institute's Leadership Council. He is also a Mentor to the LSI’s Innovation Partnership Fund.

Curran M. Simpson

Senior Vice President, Operations

Curran M. Simpson joined HGS in March 2003 as Vice President, Manufacturing Operations. He was promoted to Senior Vice President, Operations, in December 2005. Prior to joining HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen's North Carolina facility. In this role, he led the technology transfer, start-up and validation activities for Biogen's large-scale manufacturing facility, and completed a successful pre-approval inspection (PAI) resulting in commercialization of Amevive. Previous to his position with Biogen, Mr. Simpson held process development and manufacturing positions with several biotechnology companies, including Genencor, Genentech, Novo-Nordisk (U.S. and Europe) and Covance. Mr. Simpson has been involved in the scale-up and manufacturing operations for a number of commercial products, including Pulmozyme, TNKase, Herceptin and Retavase. Mr. Simpson earned his M.S. degree in Surface and Colloid Science (Physical Chemistry) from Clarkson University, and his B.S. degree in Chemical Engineering/Chemistry from the Clarkson College of Technology.

Other HGS Officers

Sally D. Bolmer, Ph.D.

Senior Vice President, Development and Regulatory Affairs

Sally D. Bolmer joined HGS in February 2000 as Vice President, Regulatory Affairs. In December 2002, Dr. Bolmer was promoted to Senior Vice President. She joined HGS from Centocor, Inc., where she held several positions, most recently Executive Director, Worldwide Regulatory Affairs. In that position, Dr. Bolmer had overall responsibility for developing and implementing Centocor's worldwide regulatory strategies for cardiovascular products. These responsibilities included overseeing the preclinical, clinical and manufacturing submissions for investigational new drugs and product licensing applications for biological and gene therapy products as well as preparation and maintenance of submissions for single- and multi-product facilities. Dr. Bolmer joined Centocor from Mount Sinai Medical Center, New York City, where she was Assistant Research Professor of Pathology. Previously, she was a Post-Doctoral Associate at Massachusetts Institute of Technology. Dr. Bolmer earned a Ph.D., in Biological Chemistry from Pennsylvania State University, and an Sc.B., in Biochemistry from Brown University. Dr. Bolmer is a member of the Regulatory Affairs Professional Society.

Diana J. Daly

Vice President, Regulatory Affairs

Diana J. Daly joined HGS in 2002 as Director, Regulatory Affairs. In 2004, Ms. Daly was promoted to Executive Director and in April 2011 to Vice President, Regulatory Affairs. In that role, Ms. Daly is responsible for strategic oversight of nonclinical, clinical, and advertising-promotion regulatory activities across the HGS product portfolio. Prior to joining HGS, Ms. Daly was with Bristol-Myers Squibb, where she held positions in Clinical Oncology Research and, most recently, was Associate Director, Oncology Strategic Unit, in the Global Regulatory Sciences department. From 1991-1996, Ms. Daly was with Glaxo Wellcome in the UK, as Clinical Program Head in the Oncology Clinical Research Department, where she led the design and conduct of global oncology trials. Prior to her 20-year career in the pharmaceutical industry, Diana was a registered nurse at Duke University Medical Center, where she coordinated industry-sponsored clinical trials in cancer patients. Ms. Daly received her Bachelor of Science degree in nursing from Indiana University of Pennsylvania.

William W. Freimuth, M.D., Ph.D.

Vice President, Clinical Research — Immunology, Rheumatology and Infectious Diseases

William W. Freimuth joined HGS in August 2000 as Director of Clinical Research, Immunology and Infectious Diseases. In December 2003, he was promoted to Vice President, Clinical Research – Immunology, Rheumatology and Infectious Diseases. Before coming to HGS, Dr. Freimuth was with Pharmacia & Upjohn, most recently serving as Therapeutic Area Clinical Director – Antiviral. He joined the Phase 1/2 clinical research unit of Upjohn in 1992 and during his tenure at Pharmacia & Upjohn held a number of clinical research management positions, including responsibility for worldwide clinical development of four antiviral agents. From 1986-1992, Dr. Freimuth completed his Residency in Internal Medicine and his Rheumatology fellowship training at the University of Michigan Medical Center in Ann Arbor. Dr. Freimuth earned his M.D. from the State University of New York at Buffalo (SUNYAB) School of Medicine, where he subsequently did postdoctoral research in immunology and immunogenetics. Dr. Freimuth received his Ph.D. in Immunology from Michigan State University, and his B.S. in microbiology from the University of Michigan.

Gilles Gallant, B.Pharm, Ph.D.

Vice President, Corporate Development

Gilles Gallant joined HGS in June 2002 as Vice President, Clinical Research – Oncology. In 2012, he became Vice President, Corporate Development. Prior to joining HGS, Dr. Gallant was Director of Clinical Oncology at Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Gallant joined Bristol-Myers Squibb in 1991 and advanced through a succession of research management positions in Canada, Europe and the United States. He played a key role in designing and directing worldwide registrational and non-registrational clinical trials of Bristol-Myers Squibb’s oncology products. Dr. Gallant received his doctorate in medicinal chemistry and bachelor’s degree in pharmacy from the Université de Montréal in Montréal (Québec) Canada. He has co-authored numerous scientific abstracts and peer-reviewed publications in the oncology research field, and is an active member of the American Society of Clinical Oncology, the American Association for Cancer Research, the European Society of Medical Oncology, the American Society of Hematology and the American Chemical Society.

Scott Habig

Vice President, Sales

Scott Habig joined HGS as Vice President, Sales, in January 2010. Mr. Habig has more than 25 years of experience as a leader in the sales and marketing of biological and pharmaceutical products for the treatment of autoimmune and infectious diseases. Prior to joining HGS, during a nine-year tenure at the Centocor and Centocor Ortho Biotech subsidiaries of Johnson & Johnson, Mr. Habig held a number of key leadership positions, including Vice President, Sales and Marketing, Centocor, and Vice President, Sales, Centocor Ortho Biotech. He developed and led the execution of sales and marketing strategy that established REMICADE (infliximab) as a leading product for the treatment of autoimmune diseases including Crohn’s disease, rheumatoid arthritis, psoriasis and ulcerative colitis. He also managed a team of more than 600 sales and marketing employees. Before Centocor, Mr. Habig served as Vice President, Marketing, at Ethicon Endo Surgery and, over a period of 14 years at Janssen Pharmaceutica, advanced through a series of sales and product management positions of increasing responsibility. Mr. Habig received his Bachelor of Arts degree in mass media communications from the University of Akron, Ohio.

Gregory F. Keenan, MD

Vice President, Medical Affairs

Gregory F. Keenan joined HGS in June 2010 as Vice President, Medical Affairs. Prior to joining HGS, Dr. Keenan spent over 10 years with Centocor Ortho Biotech, mostly recently as Leader, Worldwide Medical Affairs, Immunology Research. In that role, he oversaw the teams responsible for phase 4 trials and risk management safety research initiatives associated with the company’s immunological compounds. Previously, Dr. Keenan was an assistant professor of medicine and pediatrics at the University of Pennsylvania, with appointments in the division of rheumatology at the Hospital of the University of Pennsylvania and the section of pediatric rheumatology at the Children’s Hospital of Philadelphia. Dr. Keenan holds a B.A. degree from Colby College and an M.D. from Albany Medical College. He received residency training in internal medicine and pediatrics at the USC Medical Center and completed his fellowships in pediatric and adult rheumatology at the University of Pennsylvania. Dr. Keenan is certified by the American Board of Internal Medicine and the American Board of Pediatrics, with subspecialties in rheumatology and pediatric rheumatology. He holds memberships in the American Academy of Pediatrics and the American College of Rheumatology. Dr. Keenan is a Board Member of the Arthritis Foundation, South Eastern Pennsylvania.

Randy Maddux

Vice President, Manufacturing Operations

Randy Maddux joined HGS in March 2004 as Vice President of Quality. He was named Vice President, Manufacturing Operations, in December 2005. Prior to joining HGS, Mr. Maddux was Director of Quality at the Research Triangle Park, NC campus of Biogen Idec. In his eight years at Biogen, he established Biogen’s quality control function, including the development of systems and monitoring programs. He also led preparation activities for the commercial licensing of Biogen's Large Scale Manufacturing facility. Prior to his position with Biogen, Mr. Maddux served in a number of roles of increasing responsibility at Glaxo Wellcome at Research Triangle Park, including Supervisor of Clinical QA/QC, Group Leader of Methods Development and Automation, and Assistant Director of R&D Operations. Mr. Maddux earned a BS in Chemistry from East Carolina University and an MBA from Duke University, Fuqua School of Business.

Kevin P. McRaith

Vice President, Sales and Marketing

Kevin P. McRaith joined HGS in May 2008 as Vice President, Hepatology Franchise. In May 2009, Mr. McRaith was promoted to Vice President, Marketing. In November 2009, he was named Vice President, Sales and Marketing, with responsibility for overall oversight of sales and marketing across the HGS product portfolio, including BENLYSTA™ (belimumab) for lupus.  Mr. McRaith has more than 20 years of experience commercializing therapies for infectious diseases, oncology, neurological diseases and cardiology, and has been involved in 13 launches of new products or indications, many of which were in specialty markets similar to lupus and hepatitis C. Prior to joining HGS, Mr. McRaith was Vice President, Sales & Marketing – Hematology, Genentech Corporation, where he led commercial efforts for the top-selling biologic, Rituxan (rituximab). Before joining Genentech in 2005, Mr. McRaith served with Abbott Laboratories for 15 years, where he held a number of senior positions with responsibility for managing major product franchises, directing marketing and sales activities, and leading a number of successful launches. He also spent several years in sales and promotion with Baxter Healthcare Corporation. Mr. McRaith received his Bachelor of Science degree from the University of Iowa.

Thi-Sau Migone, Ph.D.

Vice President, Research

Thi-Sau Migone, Ph.D., joined HGS in 1999 as a Senior Scientist in the Immunology Department. She later served as Executive Director, Clinical Immunology Department before being promoted to Vice President, Research, in March, 2011. In her current position, she oversees four functional areas within research: Clinical Immunoassays, Oncology Research, Immunology Research and Lead Development. Dr. Migone received her Doctoral Degree in Biological Sciences from the University of Pavia, Italy in 1991. She completed her postgraduate professional apprenticeship in the Laboratory of AIDS-Immunopathogenesis at the Ospedale San Raffaele in Milan, Italy. Prior to joining HGS, Dr. Migone held post-doctoral positions at DNAX Research Institute, as well as the National Heart, Lung and Blood Institutes and National Institutes of Allergy and Infectious Disease, both at the National Institutes of Health.

Joseph A. Morin

Vice President, Engineering

Joseph (Joe) A. Morin joined HGS in 1997 as Senior Director of Capital Projects and Facilities. He was promoted to Vice President of Capital Projects, Facilities, and Engineering in October 2002. Prior to joining HGS, Mr. Morin served in a succession of project engineering roles of increasing responsibility at Celltech Biologics, now Lonza Biologics. While at Celltech, Mr. Morin was responsible for engineering, procurement, and construction management, from initial concept through to installation qualification, for large and small capital projects, including the initial construction and ultimate qualification of the Company’s biologics manufacturing facility. Mr. Morin began his career in construction and then as an engineer with Appledore Engineering, Inc., where he worked on large civil, structural and marine projects. Mr. Morin received his bachelor of science in industrial technology at the University System of New Hampshire’s Keene State College.

Anthony S. Murabito

Vice President and Chief Information Officer

Anthony (Tony) S. Murabito joined HGS in September 2011 as Vice President and Chief Information Officer. Prior to joining HGS, Mr. Murabito spent over eight years as Chief Information Officer at Cubist Pharmaceuticals, where he directed a complex IT environment including numerous development and architecture projects in support of commercial, research, business and collaboration partners. From 2001 to 2003, Mr. Murabito was Vice President, Information Technology and Corporate Services for Transkaryotic Therapies where in addition to Information Technology, Mr. Murabito was responsible for facilities, site construction, office and lab services. He was previously with SmithKline Beecham for almost 20 years, with responsibility for global R&D information systems. Mr. Murabito is a Registered Pharmacist and a member of the Pennsylvania and New Jersey Society of Health System Pharmacists. He received his B.S. in Pharmacy from Philadelphia College of Pharmacy and Science and an M.S. in Health Administration and Information Sciences from Widener University. He is a member of the New England CIO Biotech Forum and the TIBCO CIO Advisory Board.

Daniel J. Odenheimer, Ph.D.

Vice President, Clinical Research — General Medicine

Daniel Odenheimer joined the HGS drug development team in 1998. In 2003, he was promoted to Vice President, Clinical Research - General Medicine. Dr. Odenheimer's responsibilities include developing clinical plans for new products, designing clinical trials, and recruiting and monitoring clinical trial investigators for clinical trials. Prior to joining HGS, Dr. Odenheimer worked at British Biotech Inc., where he was Director, U.S. Clinical Research. Among his responsibilities were directing the U.S. clinical development of marimastat in lung cancer and non-oncology indications. Previously, Dr. Odenheimer worked at Boehringer Mannheim Corporation's Therapeutics division. During his eight years there, he advanced through a series of positions, including Director, Department of Clinical Research. Dr. Odenheimer earned a Ph.D. in Epidemiology and an M.S. degree in Biostatistics at the University of Michigan. He earned an M.S. in Epidemiology and a B.S. in Genetics from the University of California, Berkeley.

Jerry Parrott

Vice President, Corporate Communications and Public Policy

Jerry Parrott joined HGS in July 2001 as Vice President, Corporate Communications and Public Policy. As Principal of Policy Advocates, Inc., from 1995-2001, Mr. Parrott’s clients included HGS, Bristol-Myers Squibb, Ciba-Geigy, Diversa, Genentech, HealthCare Ventures, Hoffmann-La Roche, Western Digital and Wyeth. During this period, he helped take public both 3-Dimensional Pharmaceuticals, subsequently acquired by Johnson & Johnson, and InforMax, Inc., subsequently acquired by Invitrogen. He previously held senior policy and corporate communications management positions with Bristol-Myers Squibb Company (1979-1995), American Hospital Supply Corporation (1976-1979), and Walgreen Company (1973-1976). Mr. Parrott has helped launch important therapeutic products in immunology, oncology, infectious disease and pain relief, and has helped bring two prescription products over the counter. He received his B.A. from the University of South Florida and attended graduate school as a University Fellow at Northwestern University. Mr. Parrott currently serves as Chair of the Board of Directors of Maryland Health Care Product Development Corporation, Senior Advisor to the Maryland Life Sciences Advisory Board, and as a Director of the Tech Council of Maryland, MdBio and BioHealth Innovation, Inc. He formerly served as Chair of the Biotechnology Industry Organization (BIO) Committee on Outreach and Alliance Development, Chair of the Rx Partners health care reform coalition, Founding Trustee of the Foundation for Genetic Medicine, and Trustee of the Committee for Economic Development.

Tuomo Pätsi

Vice President, Europe

Tuomo Pätsi joined HGS in August, 2010 as Vice President, Europe. In that role, Mr. Pätsi is responsible for European sales, marketing and medical affairs across the HGS product portfolio. Previously, Mr. Pätsi held several leadership positions at Celgene International where, in 2006, he was one of the first employees in the company’s European commercial organization. His most recent position at Celgene was Regional Vice President – Northern Europe. Prior to joining Celgene, Mr. Pätsi was with Amgen, Inc. for eleven years, serving in a number of senior brand management and marketing positions, including Director of Global Marketing. Prior to Amgen, he held product management and clinical research positions in Europe with Rhône-Polenc Rorer and Eli Lilly. Mr. Pätsi is a registered pharmacist with a Master of Science degree in pharmacology from the Helsinki University School of Pharmacy, Finland.

Thomas M. Spitznagel, Ph.D.

Vice President, BioPharmaceutical Development

Thomas M. Spitznagel joined HGS in March 1998 as Group Leader, Formulation. Dr. Spitznagel has moved through a number of positions of increasing responsibility, including oversight of Analytical Development, Drug Delivery, Purification Sciences, Fermentation and Cell Culture Sciences, and Global Project Management. He was promoted to Vice President, BioPharmaceutical Development in May 2008. Prior to joining HGS, Dr. Spitznagel was a Senior Scientist at Nabi Biopharmaceuticals from 1996-1998, and a Staff Engineer at Genetics Institute from 1992-1996. During his tenure at Nabi, Dr. Spitznagel was responsible for scale-up and development of the purification process for polysaccharide-protein conjugate vaccines. During his tenure at Genetics Institute, Dr. Spitznagel was responsible for formulation and delivery system development for rhBMP-2, as well as finished product process development. Dr. Spitznagel earned his BS in Chemical Engineering at M.I.T, and his Ph.D. in Chemical Engineering at the University of California, Berkeley.

Sarah Thomas

Vice President, Quality

Sarah Thomas joined HGS in 2003 as Director of Quality Assurance. She was promoted to Vice President, Quality in 2007. In her current position she is responsible for the Quality Assurance and Quality Control functions at HGS. Prior to joining HGS, Ms. Thomas held positions in Quality Assurance with increasing levels of responsibility at several biotechnology and pharmaceutical firms including Cell Genesys, Alza Corporation, Sequus Pharmaceuticals, Syntex and Adria-SP. In her career she has worked with products at various stages of clinical and commercial development, guiding Quality programs through the transition from clinical to commercial manufacturing, including Pre-Approval Inspection and commercial launch. Ms. Thomas earned an M.B.A. from George Washington University and a B.S. in Chemistry from Butler University.

Michele M. Wales, Ph.D., J.D.

Vice President, Intellectual Property

Michele M. Wales joined the HGS Intellectual Property department in 1998, and was promoted to Vice President, Intellectual Property, in 2007. Prior to HGS, Dr. Wales was with the intellectual property law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., where she began her legal career in 1995. Dr. Wales earned her Ph.D. in human genetics and molecular biology from The Johns Hopkins Medical School, where she did post-doctoral work in the Department of Oncology. She earned her J.D. from George Washington University National Law Center, and her B.S. cum laude in molecular and cellular biology from the University of Connecticut. While at Johns Hopkins, Dr. Wales co-discovered and characterized the novel tumor suppressor gene, HIC-1, which is associated with the development of a number of cancers and for which patents have been granted.

Ann L. Wang

Vice President, Clinical Operations

Ann L. Wang joined HGS as Director of Clinical Operations in December 2000. She was promoted to Vice President, Clinical Operations in December 2003. Prior to HGS, Ms. Wang was Director of Clinical Operations for Pharmaceutical Research Associates International (PRA), a contract research organization where she was responsible for directing delivery of clinical trials services to PRA clients. From 1988-1998, Ms. Wang advanced through a series of clinical operations positions of increasing responsibility at Centocor, Inc., ultimately serving as Associate Director, Clinical Operations and Administration. While at Centocor, she led implementation of the program leading to worldwide approval of the recombinant antiplatelet drug, ReoPro. Ms. Wang began her career in as a bench scientist, first at the Lombardi Cancer Research Center of Georgetown University and then at SmithKline & French, where she was responsible for establishing a Molecular Oncology laboratory. Ms. Wang earned her B.A. in Organismal Biology at The Johns Hopkins University and did postgraduate work at Georgetown University in physiology.